Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for pancreatic cancer patients.

Joe Saseen explains how persistent cholesterol myths undermine care and why emerging oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors could expand access to intensive LDL-C lowering.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Pharmacists play a critical role in improving access to and affordability of GLP-1 therapies.

Pharmacists play a vital role in managing multiple sclerosis treatments, enhancing patient care through clinical trials and personalized therapy options.